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Protein phosphorylation plays a central role in many signal transduction pathways that mediate
biologicalprocesses.Novelquantitative mass spectrometry-basedmethods have recently revealed
phosphorylation dynamics in animals, yeast, and plants. These methods are important for our
understanding of how differential phosphorylation participates in translating distinct signals
into proper physiological responses, and shifted research towards screening for potential cancer
therapies and in-depth analysis of phosphoproteomes. In this review, we aim to describe current
progress in quantitative phosphoproteomics. This emerging field has changed numerous static
pathways into dynamic signaling networks, and revealed protein kinase networks that underlie
adaptation to environmental stimuli. Mass spectrometry enables high-throughput and high-
quality analysis of differential phosphorylation at a site-specific level. Although determination of
differential phosphorylation between treatments is analogous to detecting differential gene
expression, the large body of statistical techniques that has been developed for analysis of differ-
ential gene expression is not generally applied for detecting differential phosphorylation. We
suggest possible improvements for analysis of quantitative phosphorylation by increasing the
number of biological replicates and adapting statistical tests used for gene expression profiling
and widely implemented in freely available software tools.
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1 Introduction
Reversible protein phosphorylation in multicellular organ-
isms is mediated by the opposite action of large families of
protein kinases and protein phosphatases. The MS-based
studies have given great insight into the number and
diversity of phosphorylation events. A revolution was
caused by the development of large-scale, gel-free ap-
proaches that enabled the identification of multiple phos-
phorylation sites from small protein amounts by MS [1].
The number of sites identified in single studies almost
double each year, revealing the complexity of the phospho-
proteome of multicellular organisms by reporting more
than 10000 phosphorylation sites on several thousand
proteins in a single cell line [2]. Such analyses are enabled
by the development of protocols for highly selective phos-
phopeptide isolation from complex starting samples [3].
Although phosphopeptide sequencing by MS has met
some difficulties [4], new technological developments have
considerably facilitated this process [5].
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During the last years, MS-based studies have pro-
vided a wealth of information on the protein phospho-
rylation events in organisms ranging from bacteria to
humans. One of the outcomes is that protein phospho-
rylation can occur extremely rapid: For example, initia-
tion of receptor tyrosine kinase (RTK) phosphorylation
starts within seconds after stimulus application [6].
Moreover, it turned out that protein phosphorylation is
an abundant process: multicellular eukaryotes contain
hundreds to more than a thousand of protein kinases
that collectively target an immense number of sites.
Another result of these studies is that protein phospho-
rylation is an extremely complex mechanism: it was
found that a given phosphoprotein is often targeted by
distinct kinases at different sites. Moreover, some sites
are targeted by several different kinases [7]. Phosphoryl-
ation events can have major impacts on the conforma-
tion [8] or charge of a protein [9, 10], thereby regulating
protein activity, localization and stability. In addition,
phosphorylation sites can connect proteins to down-
stream events by direct interaction with signaling pro-
teins that contain specific phosphomotif-binding protein
d o m a i n s[ 1 1 ] .T h ea n a l y s i so ft h ea b u n d a n c eo fp h o s -
phorylation sites revealed that the large majority occurs
on serine and threonine residues. Despite the fact that
tyrosine phosphorylation is of low abundance, it is very
dynamic [12–14] and can build extensive networks with
interaction partners through their specific binding
domains, such as Src homology 2 domains [15–18] and
phosphotyrosine-binding domains [11].
Given the large number of phosphorylation events
and phosphoproteins identified, the next question to
tackle is how kinases choose between potential sub-
strates [7]. Although it was originally thought that pro-
tein kinases should work like typical enzymes, i.e.t h a t
they should phosphorylate a large number of substrates
in a minimum of time, it became apparent that most
protein kinase-substrate interactions do not obey this
rule, and are mostly occupied in excluding unwanted
phosphorylations. The spatiotemporal regulation of
components of signaling networks is extremely impor-
tant for coordinating kinase specificity [19]. Therefore,
the compartmentalization of protein kinases with their
substrates, for instance by targeting to specific mem-
branes, contributes to this process [7, 20].
Quantitative phosphoproteomic analyses have
provided great insight into signaling networks and
allowed to generate models for functional testing. In this
review, we excluded the discussion of quantitative
proteomics methods using antibody microarrays [21],
protein chips [22, 23], or gel-based approaches [24, 25].
Instead, we focus on quantitative phosphoproteomic
analysis by gel-free methods coupled to MS. For sub-
sequent data analysis, we propose to apply statistical
methods that are already well established in tran-
scriptome research.
2 Complexity and regulation of
phosphoproteomes: How many sites
make up a phosphoproteome?
Because of the low abundance of phosphopeptides in start-
ing samples, phosphopeptides must be isolated specifically
from such complex mixtures. Most commonly, phospho-
peptides are captured from complex peptide mixtures by
IMAC [1], titanium dioxide (TiO2) [26, 27] or phosphor-
amidate chemistry (PAC) [28, 29]. Each of these methods
has a bias towards a subfraction of the proteome [30, 31],
and the combined use of these three methods recently
allowed the identification of more than 10000 sites in a
single fruit fly (Drosophila melanogaster) cell type [2]. Al-
though this study combined phosphosites detected in sam-
ples isolated during different growth conditions of the cells,
this suggests that the estimation that around 30% of all
proteins can become phosphorylated at any given time
holds true [2]. However, it is likely that this number could
be as high as 50%, because the use of a single protease to
digest the proteins and the intrinsic limitations of mass
spectrometry restricted the coverage of the proteome in this
study [2]. The phosphoproteome of a multicellular eukary-
ote may thus consist of 50 000–100000 sites. Large-scale
studies suggest that tyrosine phosphorylation represents an
estimated 1–3% of the total phosphoproteome in animals
[2, 32]. If this were true, the identified 4551 phosphotyr-
osine sites from lung cancer cells [33] suggest that 100000
sites is a reasonable estimation. Whether plants, with a
protein kinase repertoire twice as large as humans [34],
contain even more complex phosphoproteomes remains to
be determined.
In contrast to the highly complex phosphoproteomes of
eukaryotic organisms, the phosphoproteome of the bacteria
Bacillus subtilis and Escherichia coli are far less complex. In
comparable approaches, when 6600 phosphorylation sites
were identified on human proteins [32], only 78 and 81 sites
were detected on a similar number of B. subtilis and E. coli
proteins [35, 36]. These studies revealed that protein phos-
phorylation on serine, threonine and tyrosine residues is
ancient, but that diversification of protein kinases and their
targets is a hallmark of eukaryote evolution.
3 Experimental approaches for
quantitative MS-based
phosphoproteomics
Now that different techniques allow automated large-scale
mapping of phosphorylation sites [37], research shifted to-
wards a more functional approach: to quantify changes in
the phosphoproteome. Techniques used for quantitative
(phospho)proteomics [38, 39] and software programs to sup-
port analysis of data generated by quantitative proteomic
approaches [40] have been described elsewhere and will not
be discussed in much detail in this review.
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Since quantitative analysis of the entire phosphopro-
teome is not yet feasible, pre-fractionation of samples is
required.In addition to the specificphosphopeptide isolation
methods such as IMACand TiO2, protein samples have been
pre-fractionated to focus on cytosolic, plasma membrane or
nuclear compartments. In addition, peptide mixtures have
been simplified by different methods such as strong cationic
exchange chromatography, immunoprecipitation with anti-
phosphotyrosine antibodies [12, 38] and hydrophilic-interac-
tion chromatography [5]. By these means, early events were
unraveled for many signaling networks. Time courses have
allowed the separation of phosphorylation events into (very)
early versus intermediate and late processes [6, 32, 41].
3.1 Techniques for quantitative proteomics
Workflows for MS-based quantitative proteomics and their
benefits and pitfalls have recently been described [38, 40].
Here, we give a short overview of several commonly and
successfully used methods that allow relative quantification
of peptides. Approaches to absolutely quantify peptides [42,
43] are much more complicated, but targeted [44] and large-
scale [45] absolute quantification determined that the stoi-
chiometry of phosphorylation sites lies between 5 and 100%.
This information is crucial to interpret quantitative analysis
of individual sites, as a twofold increase can indicate an
increase from 2 to 4%, but also from 50 to 100%. Label-free
quantification is also possible, albeit more time-consuming
[46]. Stable isotope labeling usually gives the most reliable
results for quantification. In vivo labeling excludes the need
to handle the samples separately since samples are pooled
before protein purification.
Stable isotope labeling by amino acids in cell culture
(SILAC) is an in vivo labeling technique that labels proteins
with isotopic amino acids such as
13C6-Arg or -Lys and
15N4-Arg or -Lys [47, 48]. Additionally, the isotopes
13C6-
15N4-Arg or -Lys can be used to obtain an extra time-point
sample. SILAC has been extensively used for (phospho)-
protein quantification and already more than 80 articles
were published at the beginning of 2008 (http://www.sila-
c.org/publications). SILAC with 13C6-Arg suffers from
metabolic conversion of Arg to Pro [49], but depending on
the amount used for labeling this does not always occur
extensively [50]. This method was believed to be only ap-
plicable to dividing cell culture systems, but non-dividing,
differentiated cells have now been successfully SILAC-
labeled and used to study brain-derived neurotrophic fac-
tor-induced signaling [51]. SILAC-based studies have pro-
vided the greatest numbers in terms of phosphopeptide
quantifications in independent studies, but demanded
many MS analyses [13, 32, 52–55].
Another commonly used method is based on isobaric
tags for relative and absolute quantitation (iTRAQ), which
is a four- or eight-plex reaction to label N termini of pep-
tides in vitro after digestion [56, 57]. A main benefit is that
the multiplex iTRAQ reagents allow time-course profiling
of phosphorylation-dependent signaling by applying a sin-
gle reaction to a mass spectrometer. A drawback is that
labeling occurs at a late step during the protocol (after
protein digestion), which can introduce some technical
variation.
In vivo labeling of proteins with
14N/
15N pairs can be
achieved by supplying
14N- and
15N-containing amino acids
(in case of SILAC) orK
15NO3 and (
15NH4)2SO4. The latter two
compounds can be used for labeling of plant cells [58] or
entire plants [59], but in this case hampers automated
assignment of heavy and light peptide pairs in MS analysis
because the number of N atoms per peptide differs [60, 61].
The
14N/
15N labeling has been successfully used for yeast,
plants and animals [62], and used for instance for quantita-
tive phosphoproteomic profiling of the tumor necrosis factor
pathway [63] and for plant-defense signaling [58].
3.2 Changes in the phosphoproteome induced by
stimuli
Large-scale quantitative analysis has shown that 10–20% of
the phosphorylation sites change in abundance within 30
minutes after application of one specific stress [32, 52, 64,
65]. Most changes are less than tenfold, suggesting that
phosphoproteome dynamics is expressed in changes of
threshold levels rather that on-off phosphorylation. Phos-
phorylation cascades are activated within seconds after per-
ception of signals [6], and most changes occur transiently
within 30 min [13, 32].
In one of the first studies using SILAC, changes in the
yeast phosphoproteome in response to pheromone were
reported [64]. The use of a mass spectrometer with high
mass accuracy enabled the identification of 139 differentially
regulated phosphopeptides, of which 89 were induced and
42 down-regulated after 2 h of pheromone treatment. Several
known pheromone-induced phosphorylation events in the
canonical pheromone signaling pathway were observed,
such as tyrosine phosphorylation of the mitogen-activated
protein kinase Fus3p and its substrate Far1p. Moreover,
many novel events in this already well-studied pathway were
discovered [64].
Benschop et al. [58] aimed to unravel the immediate sig-
naling responses to two pathogen-derived elicitors that are
both recognized by plasma membrane receptors. Distinct
but overlapping sets of phosphorylation events were trig-
geredby these signals, suggesting that signaling specificity is
rapidly translated into different phosphorylation profiles
[58]. A complementary study focused on differential phos-
phorylation of plasma membrane proteins induced by the
bacterial pathogen-derived elicitor flagellin in the plant Ara-
bidopsis thaliana [66]. Despite the differencesin experimental
setup and analysis (a combination of in vitro iTRAQ labeling
and IMACversusin vivo 14N/15N labeling and TiO2), fiveofthe
11 non-redundant differential phosphopeptides were also
quantified by Benschop et al. [58] and all were found to be
induced as well.
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4 Integrating information to construct
phosphorylation networks
To establish phosphorylation-dependent signaling cas-
cades one needs to identify both the phosphorylation
events and link these to the upstream kinases and
phosphatases. Whereas traditionally substrates were
identified from the kinase as starting point, now phos-
phorylation sites are described without having direct
knowledge of the responsible kinases. A daunting task
remains to enable high-throughput discovery of direct
links between substrates and protein kinases and phos-
phatases.
4.1 MS-based screening for protein kinase targets
The phosphosite with one or more surrounding amino
acids together constitute the kinase motif, which is an
essential piece of information to link a phosphosite to
the upstream kinase. These usually consist of one or a
few required residues in close vicinity of the phospho-
rylated amino acid [7]. Kinase motifs are, however, not
enough for the assignment to the responsible kinase,
and recently it was found that contextual information is
essential [67]. Large-scale analyses such as gene co-
expression and protein-protein interactions provide such
information and in many cases allow linkage of a par-
ticular kinase isoform to specific phosphorylation sites
[67]. The networKIN algorithm takes context into
account, thereby enabling the construction of protein
phosphorylation networks [67]. Using data obtained from
protein and peptide chips aids in this analysis [23, 34,
38, 68]. Optimization of this algorithm promises to con-
tribute significantly to connect the continuously increas-
ing number of phosphorylation sites to specific kinases.
Two experimental approaches have recently identified
ataxia-telangiectasia, mutated (ATM) and ATM and Rad3-
related (ATR) kinase networks involved in DNA damage
signaling. A first study described 700 putative ATM and
ATR targets by using 68 phosphomotif (pSQ/pTQ)-spe-
cific antibodies and subsequent MS-based identification
of the target sites [69]. This elegant approach shows that
antibodies against phosphomotifs, in addition to phos-
photyrosine antibodies, enable the selection of sub-
populations of the phosphoproteome specific to a kinase
(group). In a second study, the phosphorylation network
induced by UV light was examined and overlapped with
pSQ/pTQ sites identified from UV-treated cells by a
peptide affinity approach using antibodies [70]. In addi-
tion, UV-induced phosphorylation was measured in con-
trol and ATR-deficient cell lines. The 19 UV-induced SQ/
TQ sites were found to decrease in the ATR mutant line
and are thus good ATR candidate target sites [70]. More-
over, these studies provide a rich source of information
to train the NetworKIN algorithm [67].
4.2 Differential phosphorylation profiling enables
mapping of signaling cascades
Globally oriented approaches have identified numerous
known and novel phosphorylation events in classical signal-
ing pathways, even in well-studied cascades. A global
approach using quantitative MS recently showed aspects of
cell migration [71]. Spatial organization of signaling net-
works was unraveled by phosphopeptide isolation from non-
motile and motile compartments of chemotactic cells. Sub-
sequent relative quantification of 3509 proteins and 228
phosphorylation sites revealed great insight into cell motility
and spatial regulation of signaling networks.
Large-scale temporal analysis of tyrosine phosphoryla-
tion events during immune responses in mast cells was
conducted [72]. Relative phosphorylation ratios of hundreds
of sites were determined across nine time points in two dif-
ferent cell lines. Phosphorylation sites were clustered using
fuzzy k-means according to their dynamic behavior during
the immune response [72]. Others have clustered phospho-
rylation profiles using self-organizing maps [13] or fuzzy c-
means [32].
One of the best-described signaling pathways is the one
downstream of the epidermal growth factor receptor (EGFR)
[73, 74]. Dimerization, trafficking through endosomal com-
partments and turnover is critical for regulation of EGFR
signaling to downstream effectors [75, 76]. This highlights
the complexity and stringency of regulation of EGFR signal-
ing to execute proper physiological responses. Activation of
the EGFR leads to differential phosphorylation on serine,
threonine and tyrosine residues of more than a thousand
proteins [13, 32, 52–55].
4.3 Modeling of phosphorylation-dependent
signaling pathways
Proteomics data are very suitable to be analyzed by systems
biology approaches to establish and model pathways [77].
Protein phosphorylation events in the ERBB2/HER2 and
EGFR signaling network were combined with protein-pro-
tein interaction data and modeled, revealing novel links [78].
In two elegant studies, Wolf-Yadlin et al. [79] and Kumar
et al. [80] showed the effect of ERBB2/HER2 overexpression
on the tyrosine phosphoproteome after EGF or heregulin
(HRG) application. By a quantitative MS-based approach,
they identified a large number of regulated phosphosites,
and they analyzed the relationship between specific phos-
phorylation sites and downstream biological behavior. This
showed that EGF and HRG activate multiple or single path-
ways, respectively, to stimulate the same biological response
(migration). Moreover, using partial least-squares regression
(PLSR) analysis, a reduced number of phosphosites most
strongly correlating with proliferation and migration were
discovered and termed a “network gauge” [79, 80]. Such an
approach might prove to be extremely important for select-
ing candidates for targeted experiments in future research.
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4.4 Using knowledge of the phosphoproteome for
cancer therapy
The challenge to use obtained networks for novel drug
development has been initiated. Mutations in RTKs are
involved in many cancers and are successful drug targets
[81]. This allows dissection of drug actions and perhaps aid
in further drug optimization and development. EGFR and c-
METare RTKs that share part of an extensive signaling net-
work involving many tyrosine phosphorylation events, which
collapse by application of their inhibitors [53]. EGFRvIII is a
hyperactive EGF receptor mutant that plays an important
role in glioblastoma (aggressive brain tumor) behavior, and
confers resistance against the EGFR inhibitor gefitinib.
Huang et al. [54] dissect the phosphotyrosine signaling net-
work triggered by EGFRvIII. The authors carefully examined
the network and identified c-MET as being activated in
EGFRvIII-carrying glioblastomas. The c-MET amplification
bypasses inhibition of hyperactive EGFR mutants by gefiti-
nib through activating a cell survival pathway [82]. Resistance
against EGFR inhibitors occurs in most glioblastomas and
lung cancers with activating EGFR mutations, but can be
defeated by a combinatorial application of both EGFR and c-
MET inhibitors [54, 82]. Thus, chemoresistance can be
caused by coexpression of different active RTKs, and phos-
phorylationprofilingofRTKsincancercellscanrevealtargets
for such therapies [33, 54, 82]. These systematic approaches
arethuscapableofprovidinghandlestocombatcancer[83].
Many chemical kinase inhibitors have been used to treat
cancers. Although several have been used successfully for
many years now, major questions have remained about the
mechanisms underlying side effects and drug resistance.
Quantitative analysis of kinase inhibitors has recently shown
that most clinically used kinase inhibitors are aspecific [84,
85]. A large-scale, semiquantitative approach to profile tyro-
sine phosphorylation showed the expression of active RTKs
in different lung cancers, implicating these RTKs in the dis-
ease [33]. As mentioned above, these kinases are attractive
targets for therapeutic use. In conclusion, these studies gave
first insights into the specificities of these cancer drugs and
how they affect downstream signaling pathways and may
ultimately serve the treatment of cancers.
5 Statistical methods for deciding
differential phosphorylation
With the introduction of highly accurate mass spectro-
meters, it is feasible to obtain statistically significant protein
identifications. However, proteins are usually identified by at
least two peptides, whereas phosphorylation sites only by
single peptides. Since different phosphorylation sites on the
same protein usually behave differently [32], each phospho-
site has to be evaluated and quantified individually. In addi-
tion, quantification of multiply phosphorylated peptides has
to be carefully evaluated because of the distinct behavior of
individual phosphosites. Here, we review and discuss statis-
tical issues related to deciding when a phosphosite is differ-
entially phosphorylated between two conditions. The basic
question that we seek to answer here is whether there is a
significant difference between the degrees of phosphoryla-
tion of the phosphosite at two conditions (e.g. stressed vs.
non-stressed, mutant vs. wild type) with the goal to find out
which phosphosites have changed due to stress or mutation.
As discussed in previous sections, phosphoproteomic
techniques usually produce relative rather than absolute
phosphorylation changes: ratios between the areas of two
peaks are taken. This is analogous to cDNA microarray
analysis, where two samples are hybridized with different
color dyes and loaded on one spot. The analysis of differ-
ential gene-expressionhas grown into a whole new branch of
statistic research in recent years, and resulted in the devel-
opment of many new techniques. Because of the analogy,
many results of this research should be directly applicable to
the emerging area of phosphoproteomics for selecting dif-
ferentially phosphorylated phosphosites.
In order to make reliable decisions if a phosphosite is
differentially phosphorylated, repeated experimental meas-
urements are necessary, followed by the following steps:
(i) Formulating a null-hypothesis: in this case, the hy-
pothesis that the mean phosphorylation degree of the phos-
phosite in condition 1 is equal to its mean phosphorylation
degree in condition 2. Because ratios between the phospho-
rylation degrees are taken, the hypothesis will thus be that
the ratio is equal to 1 (or 0 in case log-ratios are considered,
which is commonly done for gene expression because it
usually makes the data more normally distributed, and
would also be favorable for phosphorylation degree ratios).
Rejecting the null-hypothesis means accepting that a phos-
phosite is differentially phosphorylated.
(ii) Choosing the suitable statistics. This will depend on
the particular assumptions on the distributions, i.e. when the
data are normally distributed particular tests are used; other
tests when this is not the case.
(iii) Selecting the cut-off for significant statistics: this is a
crucial step in which the actual decision is made when to
consider a phosphosite to be differentially phosphorylated
due to the change in condition and not just a fluctuation due
to intrinsic biological variance. Usually this decision is made
based on p-values obtained from the test statistics.
Without repeated measurements it is not possible to
perform the required testing. Like in the early days of cDNA-
expression data analysis, several recent works in phospho-
proteomicsmake useofthe concept of ‘fold change’ to decide
if phosphosites are differentially phosphorylated. The
observed fold change in a single experiment, no matter how
large, is not a justified way to decide about differential phos-
phorylation, as one needs to measure the biological varia-
bility inside each of the conditions in order to assess if the
change is due to the different conditions or just due to
intrinsic variability. The fold-change approach might incor-
rectly select phosphosites with large fold change, and miss
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com4458 S. de la Fuente van Bentem et al. Proteomics 2008, 8, 4453–4465
truly differentially phosphorylated phosphosites with small
fold changes. An improvement of the fold-change approach
is applied by Benschop et al. [58] and Nühse et al. [66] in their
studies on differential phosphorylation in A. thaliana. They
select a fold-change cut-off and check if sites pass this
threshold in several biological replicates, thereby excluding
sites with large intrinsic variability. Benschop et al. [58] per-
formed two biological replicates and selected only sites,
which showed 1.5-fold change (up or down) in both repli-
cates. This indeed emphasizes the need for replication: in
one biological sample 88 differential sites were identified,
while in the other only ten sites were identified and of these
eight sites overlapped with the previous biological replicate.
Nühse et al. [66] performed more than two independent bio-
logical experiments and accepted only two-fold changes that
were seen in two or more experiments. Their approach still
has limitations, since it will miss sites that change in re-
sponse to the applied conditions, but with small fold change.
In addition, no motivation is provided as to why the particu-
lar fold-change threshold isselected:what is a better number,
1.5 or 2? A recent method proposed for gene expression data
[86] formalized the approach employed by Benschop et al.
[58] and Nühse et al. [66]. In their method, genes are ranked
according to their fold change and the consistent appearance
of a gene in either the top (T) or bottom (B) of the ranking
across the replicates is the criterion for differential expres-
sion. No arbitrary fold-change threshold is taken. Rather, the
size of top T and bottom B is decided based on how many
differential phosphorylation findings are made at a particu-
lar size of Tand B and compared to the number of expected
incorrect findings at that Tand B. Evaluating this at different
sizes of T and B one can select an acceptable fraction of
incorrect findings [also referred to as false discovery rate
(FDR), see below for more details]. The latter is a very strong
aspect of this approach. Rather than choosing an arbitrary
threshold that gives no indication of how confident one can
be about the findings, now the threshold can be selected
according to a tolerable percentage of wrong discoveries.The
authors showed that at FDR level of 0.02 (meaning that out
of 100 discoveries two are expected to be wrong) of the 131
discoveries made 111 corresponded to fold changes below
1.45! These results concerned cDNA gene-expression data,
but it is likely that small fold changes in the phosphorylation
state of a particular residue play an important role in signal
transduction as well.
While the global approach by Zhou et al. [86] has its
strengths, it is more common to evaluate differential expres-
sion for each gene one at a time. The simplest way of for-
mally correct testing for differential expression/phosphoryl-
ation is the t-test, employed for example by Zhang et al. [13]
to test for differential tyrosine phosphorylation between dif-
ferent EGFR stimulations. Over a set of biological replicates,
the mean phosphorylation ratio and its standard deviation
can becalculated. Using these two quantities, a one-samplet-
test can be performed, which accounts for the specific varia-
bility of each phosphosite:
t ¼
mR
s= ﬃﬃﬃ
n
p
where mR stands for the mean log-ratio, s is its SD and n
the number of replicates. The larger the t-statistic, the
more confident one can be in the finding of a true differ-
ential phosphorylation. As is easily seen, the t-statistic
will be large whenever the mean ratio is larger than the
standard deviation, so a phosphosite can have a small
mean ratio (fold change), but if the ratio is not very vari-
able, this mean can still be considered significant. Vice
versa for large mean ratios; high variance may cause such
large ratios to be deemed insignificant. It is also clear that
the more replicates are performed, the more confident
one can be about the estimated values of mR and s.A n
adequate number of replicates are essential to assess the
intrinsic variance and tell it apart from the truly differ-
ential phosphorylation, and to make any significant state-
ment about the test result. At this time, the analysis of
replicates by MS-based quantitative phosphoproteomics is
more demanding than by gene expression experiments,
but we do need them in order to be able to make reliable
decisions on which phosphosites are differentially phos-
phorylated. When there are only few replicates available,
as is often the case with the data under consideration,
variance estimation may be unreliable. To address this
issue for gene-expression data, several modifications of
the t-test and other tests have been proposed (regularized
t-statistic [87]; SAM, Significance Analysis of Microarrays
[88]; penalized t-statistic [88, 89]; B-statistic [90]). The
many tests proposed could give widely different results
and often it is not clear which test applies best. DEDS
(Differential Expression by Distance Synthesis [91]) is an
interesting step toward synthesis of many of the above
statistics. It ranks the genes according to the multi-
dimensional distance to the point with maximum value
for each statistic.
The t-test assumes normally distributed data, but is
known to be quite robust towards deviations from nor-
mality. If the distribution is far from normal, non-para-
metric tests are preferred. For example, Trinidad et al.[ 9 2 ]
applied the Mann-Whitney U test to detect differential
phosphorylation between samples from hippocampus and
cerebellum. Interestingly, these authors do not test for
’differential phosphosite phosphorylation’, but rather for
’differential protein phosphorylation’ and then use several
phosphosites as ’replicated observations’ of the same pro-
tein. While from a statistical point of view this is favor-
able (because the number of ‘replicates’ of each protein is
much higher than the actual experimental replicates),
from a biological point of view it is not: it has been
shown by many studies that the majority of phosphosites
on a given phosphoprotein behave differently during
stress reactions [32].
All abovetestsare implemented in the statistical software
R, freely available at: http://www.r-project.org/.
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5.1 Choosing a threshold for differentially
phosphorylated sites
After the genes are ranked according to the chosen statistic,
the decision must be made, which of them to declare signif-
icant. The graphical methods, like Q-Q (quantile-quantile)
plot or volcano plot may be useful aid in identifying genes
with unusual fold change or t-statistics [93].
Usually the final decisions are made based on the p-
values obtained from the test statistics. The p-value threshold
‘classically’ used is 0.05, indicating the probability of observ-
ing a given value of fold change if the null-hypothesis (“the
site is not differentially phosphorylated”) is right. Since 0.05
is a rather low probability, the alternative hypothesis (“the
site is differentially phosphorylated”) is accepted. However,
the probability of obtaining a significant result just by chance
is growing along with the number of tests. Thus, when mul-
tiple tests are conducted in parallel, there is a need for
adjustment against false positives (type I error; deciding that
a site is differentially phosphorylated while it truly is not).
This can be done either by adjusting p-values or by adjusting
the significance threshold. There are two standard ap-
proaches to adjust for multiple testing. Deciding a threshold
depends on selecting a trade off between False Positives and
False Negatives.
False Positive = false discovery = wrongly rejected null
hypothesis = type Ierror= deciding that a site is differentially
phosphorylated while it truly is not
False Negative = missed discovery = wrongly accepted
null hypotheses = type II error = deciding that a site is not
differentially phosphorylated while it truly is
Family-Wise Error Rate, or overall type I error rate
(FWER) aims to control the probability of one or more false
positive results. Bonferroni correction [94] adjusts p-values
by dividing them by the total number of tests. It is the most
conservative approach: it will miss many true differential
phosphorylation events (True Positives) in order to strongly
limit the number of incorrectly accepted differential phos-
phorylation events (False Positives). The less conservative
Holm’s procedure [95] rejects the null hypotheses corre-
sponding to the k smallest p-values if pðiÞ  
a
m   i þ 1
for all
i   k, where m is the total number of tests and a is the
desired level of FWER control.
The interpretation of accepting adjusted p-value of,
say, 0.05, is that if the method were applied 100 times and
produced 100 lists of significant discoveries, only five of
these lists would be expected to contain any single false
positive. This leads to significant increase in the error II
rate (the probability of missing a true positive result, i.e.
deciding that a site is not differentially phosphorylated
while it truly is). Such a strong control is often found
unnecessary and impractical in microarray experiments
analysis. In practice, many researchers would trade the
risk of including false discovery for a stronger power of a
test.
The conceptofFalseDiscoveryRate(FDR), introducedby
Benjamini and Hochberg [96], is a less stringent alternative
to FWER and has completely revolutionized the field of
multiple hypothesis testing. FDR controls the expected pro-
portion of type I errors in a list of rejected hypotheses, or
proportion of false positives in tests declared positive. The
concept of FDR is very practical, since it provides a way to
select a threshold simply at a desired percentage of false dis-
coveries. Instead of deciding on p-values that tell how many
mistakes are made in the hypothetical situation that all null-
hypothesis are true, the FDR level simply tells how many
discoveries are expected to be false. Usually researchers are
quite satisfied with FDR levels of 0.1, meaning that 1 out of
10 discoveries is false, or even higher levels.
FDR methods set a cut-off for p-values. The Benjamini
and Hochberg [96] procedure sorts p-values in decreasing
order and rejects the hypotheses whenever their p-value is no
larger than p(k), where
mpðkÞ
k
  a( a is a desired level of FDR
control and m is the fraction of true null hypotheses). Mod-
ifications of this procedure use an estimate of the null-dis-
tribution by fitting the observed distribution of p-values [89,
97–103] or by bootstrapping [104].
Several methods for multiple hypothesis testing correc-
tions are implemented in the R-software. The Optimal Dis-
covery Procedure [105] implemented in the software EDGE
[106] maximizes expected true positives for a fixed level of
expected false positives.
5.2 Multiple conditions
In certain cases,it may beofinterest to performcomparisons
between more than two groups. Differential phosphorylation
across multiple conditions could be tested using linear
models. Linear models could represent the expression value
as a linear combination of effects from different sources of
variation [107]. The simplest, two conditions linear model is
equivalent to a t-statistic. For more than two conditions,
fixed-effects ANOVA (ANalysis Of VAriance) and F-test [93,
97, 107, 108] could be employed. As with t-test, several var-
iants ofthe F-test (e.g.global, penalized) have been developed
to improve the estimation of the variance. Mixed-effects
ANOVA is appropriate when there are many experimental
factorswith potential interactionsbetween them [109]. Freely
available software can be used to perform these analyses,
such as the MAANOVA package for R and the SAM software
[88].
5.3 Time-course experiments
The responses in signal-transduction pathways after elicita-
tion proceed dynamically over time. Measuring and analyz-
ing time responses in signal transduction may therefore be
more important than the static data discussed above. Several
phosphoproteomic data are in a form of a time course, and
more such datasets can be expected to appear in the future.
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While the analysis of time-series data is different from static
data, the main issue remains the same: identifying which
phosphosites significantly change in their degree of phos-
phorylation. Also in case of time-series, the fold-change
approach has been used [32]. However, several statistical
methods for significance analysis of time-series data have
been developed.
Like in the analysis of static data, differential phospho-
rylation could be tested between two or more groups, e.g.
testing if a protein is differentially phosphorylated over time
in an elicited series versus an un-elicited control time series.
Unlike static samples, time series provide an ordering of
observations and this allows testing for differential phos-
phorylation evenwithin a single group,e.g.simply testing if a
certain protein’s phosphorylation state changes over time
after elicitation. Statistical analysis of a time-course experi-
ment poses several difficulties arising from the facts that
such experiments are usually short, have limited number of
replicates,and that measurementsfrom the samesample are
correlated over the time. Unlike in the static data, in time-
course analysis not only the magnitude of the activity, but
also its pattern over time is of importance. The approaches
that have been applied fall in two categories: (i) Methods that
test for differential expression between pairs of time points,
and (ii) Profile based methods that explicitly consider the
whole series.
ANOVA (with time-variable) has been used for detect-
ing differential expression between each time-point in the
time-series [110]. While performing well, the drawback of
ANOVA is that it requires many replicates [111, 112]. In
addition, it does not take into account the global profile of
the time series. Profile-based models [113, 114] do not rely
on the data for particular time point only, but rather take
the overall shape of the time-course curve under account.
The approach developed by Storey et al. [113] is based on
fitting a curve to the time series, first separately for each
treatment group (e.g. elicited and control), and then using
combined data from both groups (corresponding to the
null-hypothesis that both series share the same fit). If the
individual fits are significantly better than the simulta-
neous fit (based on sum of squares using F-test), the time-
series profiles are decided to be different and thus, the
gene is declared differentially expressed between the treat-
ment groups. To detect differential expression within a
single group, it is tested whether the mean expression level
in time is significantly different from constant. This
approach is very attractive, as it does not require any
replicated measurements of the time series! However,
recently this method was compared to two methods that do
require replicated time series [111] and it was shown using
simulated data that for sparsely sampled time series (about
ten time points) the two methods completely outperform
the approach by Storey et al. [113]. For denser time series
the differences get smaller and for time series with many
points (50 time points) the approach by Storey et al. [113]
outperformed the other two. It seems that there is no way
out: many observations are needed to make reliable statis-
tical decisions, either by obtaining replicates or by obtain-
ing single, but densely sampled time series. The time-
course analysis using the algorithm by Storey et al. [113] is
implemented in the user-friendly software EDGE [106].
Other methods to detect differential expression in time se-
ries include the use of a multivariate empirical Bayes sta-
tistic [115], Wald test, accounting for autocorrelation [116],
Hidden Markov Models [117], and GSVD (Generalized
Singular Value Decomposition) [118].
5.4 Analysis of differential phosphorylation in
signaling pathways
While the analysis tools that we have discussed so far are
oriented toward finding individual phosphosites that are dif-
ferentially phosphorylated (expressed) between conditions,
the underlying questions usually aim to identify the biologi-
cal processes involved in these conditions. Ideally then, one
performs tests to find out which signal-transduction path-
ways are differentially activebetweenconditions.It may beof
interest to test whether a particular kinase is differentially
phosphorylated with all its known targets (or subsets
thereof). Besides the biological relevance, such tests are also
appreciable from a statistical point of view: the pathway-level
change in activity may be missed by the individual protein
kinase level analysis ifthe changes in individual activities are
too small to be found significant in the limited number of
experiments [119]. Considering the whole pathway, the small
changes add up and may provide enough power to establish
significance. Several tools have been developed to test for
differentially expressed gene sets; these might be applied
either to the list of genes declared significant (e.g. tools for
analysis of the overrepresentation of Gene Ontology terms;
EASE, [120]), to the whole list of genes ranked by their p-
values (GSEA [119, 121]; SAM-GS, [122]) or to the original
expression data [123]. Again, these algorithms can be
equivalently used on phosphoproteomics data for mapping
differential phosphorylation events in signaling networks.
6 Conclusions and challenges
At present, tens of thousands of phosphorylation sites and
for many their behavior during different cues have been
revealed. However, for most of the sites the responsible pro-
tein kinase has not been identified. Consequently, phospho-
rylation networks are still fragmented. A challenge remains
to couple these sites to the responsible protein kinases, but
novel algorithms and approaches have been developed to
discover kinase-substrate links [67, 68]. The experimental
verification of the in vivo kinase is, however, still a tedious
task.
Combining quantitative information on changes in
phosphoproteomes induced by kinase inhibitors, mutated
kinase forms and environmental cues, phosphorylation
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in protein complex components [44], drug action on pro-
tein kinase pathways [53, 54], kinase deletion or over-
expressing strains with bioinformatics approaches will
eventually lead to comprehensive knowledge of the dy-
namic behavior of phosphorylation networks [67, 70,
124]. Cross-talk between different PTMs exists [125], and
therefore knowledge of different modifications should be
combined. This may ultimately allow computational
modeling of signaling networks on a systems-wide scale
[126–128].
Where is the limit? With the current progress, the
first full phosphoproteome (MS limitations not taken
into account) could be solved within the next few years.
Quantitative aspects of stimulus-induced changes in the
phosphoproteome will continue to grow and modeling of
the resulting pathways will uncover many novelties.
Comprehensive profiling of physiologically relevant sig-
naling cascades could be possible by metabolic labeling
of tissues or whole multicellular organisms such as ani-
mals [129–131] and plants [59].
Proteins usually occur in many isoforms that differ
in PTMs. Some of these PTMs, such as phosphorylation
and ubiquitylation, show intricate relationships [125].
Knowledge of modifications of protein isoforms rather
than of peptides derived from these isoforms is therefore
crucial for understanding the action of individual PTMs.
Top-down proteomics, i.e. the analysis of entire proteins,
to decipher the concerted action of PTMs on single pro-
teins, will be a further challenge [132]. Although such
analysis is difficult and needs further improvement, it
offers a promising method for future proteomic research
[133].
Quantitative approaches have provided unbiased
views on signaling pathways and show that it is feasible
to generate working hypotheses from these. High-quality
data that conform to MIAPE standards [134], and the
introduction of general rules for analysis will increase
the confidence of MS data [133]. Consistency in data
processing of quantitative MS-based phosphoproteomic
approaches will likewise increase the quality and allow
comparison of datasets generated by different methods.
Large-scale, MS-based approaches have already begun to
reveal the specificities of protein kinases, their down-
stream signaling networks and how inhibitors affect
these. Functional phosphoproteomics [68] with selective
testing of obtained candidates [54, 135] may aid in
understanding and treating diseases like cancer and
neurological disorders. As described above, the first
functional tests of such hypotheses have already shown
promising results in the combat against cancer. The
analysis of individual phosphorylation sites is still tre-
mendously complicated, but the time is ripe for biologi-
cal verification of modeled signal-transduction pathways.
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